Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3  Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer
   Donald A. Berry
   See related article, p. 26

6  Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant
   Lucie M. Turcotte and Michael R. Verneris
   See related article, p. 69

CCR New Strategies

9  New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
   Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut

Molecular Pathways

16  Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
    Eytan M. Stein

Review

20  From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy
    Liufu Deng, Hua Liang, Sherry Fu, Ralph R. Weichselbaum, and Yang-Xin Fu

CANCER THERAPY: CLINICAL

26  Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
    Christos Hatziis, W. Fraser Symmans, Ya Zhang, Rebekah E. Gould, Stacy L. Moulder, Kelly K. Hunt, Maysa Abu-Khalaf, Erin W. Holtzatter, Donald Lannin, Anees B. Chagpar, and Lajos Pusztai
    See related commentary, p. 3

34  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

44  A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Martin Schlimmerber, Barbara Janzeh, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G. Martins, Lisa F. Licita, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn Burmeister, Yasuhiro Funahashi, Min Ren, James P. O’Brien, and Steven I. Sherman

54  An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
    Masanori Noguchi, Kazumasa Matsumoto, Hirotugu Uemura, Gaku Arai, Masatosh Eto, Seiji Naito, Chikara Ohyama, Yasutomo Nasu, Masatoshi Tanaka, Fukuko Moriya, Shigetaka Sukekane, Satoko Matsueda, Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, and Kyogo Itoh

61  A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Andrew H. Ko, Tanios Bakai-Saab, Jessica Van Zifile, Olga M. Mirzoeva, Nancy M. Joseph, Amir Ali Talasaz, Peter Kuhn, Margaret A. Tempero, Eric A. Collisson, R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, and W. Michael Korn

PERSONALIZED MEDICINE AND IMAGING

69  Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients
    Jennifer M. Knight, J. Douglas Rizzio, Brent R. Logan, Tao Wang, Jusfa M.G. Arevalo, Jeffrey Ma, and Steve W. Cole
    See related commentary, p. 6
Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee, Sabrina Martyx, Irina Matic, Dalia Salem, Maryalice Steeler-Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance Yuan, Janet Valdez, Susan Soto, Mohammed Z.H. Farooqui, Sarah E.M. Herman, and Adrian Wiestner

Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Lukas J.A.C. Hawinkels, Amaya Garcia de Vinuesa, Madelon Paauwe, Marianna Kruithof-de Julio, Eliza Wiernikowska, Evangelia Pardali, Laura Mezzanotte, Stijn Keereweer, Tanya M. Braumuller, Renier C. Heijkants, Jos Jonkers, Clemens W. L€owik, Marie-Jos€e Goumans, Timo L. ten Hagen, and Peter ten Dijke

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris, Paul G. Corn, Nila U. Parikh, Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana Aparicio, Anh G. Hoang, Sanchaika Gaur, Lynnelle Thorpe, Sankar N. Maity, Menashe Bar Eli, Bogdan A. Czerniak, Yiping Shao, Mian Alauddin, Sue-Hwa Lin, Christopher J. Logothetis, and Gary E. Gallick

Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo
Zheng Chen, Albert E. Teo, and Nami McCarty

Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
Gema Perez-Chacon, Carolina Martinez-Laperche, Nerera Rebolleda, Beatriz Somovilla-Crespo, Cecilia Muñoz-Calleja, Ismael Ruño, and Juan M. Zapata

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egahazi Bege, Marianne Frostvik Stol, Lambert Skoog, Lena Carlsson, Zakaria Einbeigi, Elisabet Lidbrink, Barbro Lindholm, Niklas Loman, Per-Olof Malmstr€om, Martin S€oderberg, Thomas M. Walz, Mårten Fernø, Thomas Hatzschek, and Ingrid Hedenfalk in collaboration with the TEX study group

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G. Leclerc, Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, and John Stagg

Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi, Andreas Agathangelidis, Evangelia Stalika, Maria Karypidou, Alexandra Sierenta, Achilles Anagnostopoulos, Richard Rosenquist, Anastasia Hadidimitriou, Paolo Ghia, Lesley-Ann Sutton, and Kostas Stamatopoulos

PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance

ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen, Albert E. Teo, and Nami McCarthy

Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
Florian Posch, Johannes Thaler, Gerhard-Johann Zlabinger, Oliver Konigspriigge, Silvia Koder, Christoph Zielinski, Ingrid Pabinger, and Cihan Ay

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egahazi Bege, Marianne Frostvik Stol, Lambert Skoog, Lena Carlsson, Zakaria Einbeigi, Elisabet Lidbrink, Barbro Lindholm, Niklas Loman, Per-Olof Malmstr€om, Martin S€oderberg, Thomas M. Walz, Mårten Fernø, Thomas Hatzschek, and Ingrid Hedenfalk in collaboration with the TEX study group

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G. Leclerc, Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, and John Stagg

Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi, Andreas Agathangelidis, Evangelia Stalika, Maria Karypidou, Alexandra Sierenta, Achilles Anagnostopoulos, Richard Rosenquist, Anastasia Hadidimitriou, Paolo Ghia, Lesley-Ann Sutton, and Kostas Stamatopoulos

PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance

ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen, Albert E. Teo, and Nami McCarthy

Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
Florian Posch, Johannes Thaler, Gerhard-Johann Zlabinger, Oliver Konigspriigge, Silvia Koder, Christoph Zielinski, Ingrid Pabinger, and Cihan Ay
Table of Contents

207 Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Irena Misiewicz-Krzeminska, María E. Sarasquete, Carolina Vicente-Dueñas, Patryk Kzeminski, Katarzyna Wikonska, Luis Antonio Coschete, Dalia Quwaider, Elizabeta A. Rojas, Rocio Corral, Ana A. Martin, Fernando Escalante, Abelardo Bárez, Juan Luis García, Isidro Sánchez-García, Ramón García-Sanz, Jesús F. San Miguel, and Norma C. Gutiérrez

218 Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Markus Ringnér, Göran Jönsson, and Johan Staaf

230 EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

243 Absolute Effect of Prostate Cancer Screening; Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening

250 Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
Anna Karpathakis, Harpreet Dibra, Chistodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua Francis, Duhane Oukrif, Dalvinder Mandair, Marinos Pericleous, Mullan Mohamadweh, Stefano Serra, Olagunju Ogunbiyi, Marco Novelli, TuVinh Luong, Sylvia L. Asa, Matthew Kulke, Christos Toumpanakis, Tim Meyer, Martyn Caplin, Matthew Meyerson, Stephan Beck, and Christina Thirlwell

259 The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helset, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, and Razelle Kurzrock

LETTERS TO THE EDITOR

268 Neoadjuvant as Future for Drug Development in Breast Cancer—Letter
Marc Buyse, Tomasz Burzykowski, and Everardo D. Saad

269 Neoadjuvant as Future for Drug Development in Breast Cancer—Response
Angela DeMichele, Douglas Yee, Melissa Paoloni, Don Berry, and Laura J. Esserman, on behalf of the I-SPY2 Investigators

RETRACTION

270 Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s)

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2016 American Association for Cancer Research.
ABOUT THE COVER

The cover shows a section from a patient-derived xenograft of prostate cancer grown in mice treated with the MET/VEGFR-2 inhibitor, cabozantinib. Immunohistochemical staining shows an islet of viable tumor cells surrounding a VEGFR-2-negative blood vessel, with apoptotic cells surrounding the islet. For details, see the article by Varkaris and colleagues on page 107 of this issue.